The European Medicines Agency is in talks with drug companies to explain how it would determine the protective efficacy of next-generation of COVID-19 vaccines as placebo-controlled trials are getting more difficult to undertake.
The EMA says it will be asking companies to undertake immunobridging studies until an acceptable “immune marker” of protection is...







